Home » News » Communique – May. 14, 1999

Communique – May. 14, 1999

abortion

FLORIDA: James Scott Pendegraft IV, MD, sent a letter announcing the opening of his newest abortion mill, Ft. Lauderdale Women’s Center, (FLWC). He wrote “To obtain a pregnancy termination beyond 24 weeks gestation, Florida state law requires that a patient receive a written statement from her personal physician indicating it would be a threat to her health to continue the pregnancy. Additionally, FLWC will offer chemically induced terminations using the combination of Methotrexate and Misoprostol between 3 to 9 weeks gestation for those patients who prefer to not undergo a procedure which involves the use of surgical instruments. Manual Vacuum Aspiration (MVA) can also be performed on patients between three to nine weeks gestation if the patient chooses.” Pendegraft describes himself as a perinatologist and board-certified Ob/Gyn.

James Scott Pendegraft IV, MD, sent a letter announcing the opening of his newest abortion mill, Ft. Lauderdale Women’s Center, (FLWC). He wrote “To obtain a pregnancy termination beyond 24 weeks gestation, Florida state law requires that a patient receive a written statement from her personal physician indicating it would be a threat to her health to continue the pregnancy. Additionally, FLWC will offer chemically induced terminations using the combination of Methotrexate and Misoprostol between 3 to 9 weeks gestation for those patients who prefer to not undergo a procedure which involves the use of surgical instruments. Manual Vacuum Aspiration (MVA) can also be performed on patients between three to nine weeks gestation if the patient chooses.” Pendegraft describes himself as a perinatologist and board-certified Ob/Gyn.

(Reading: 4/14/99 letter to Kathi A. Aultman, MD from James Scott Pendegraft IV, M.D.)

GENETIC TERMINATION: The Calgary Sun reports on one child whose parents were told to abort him at 24 weeks because “his small bowel was forming outside his abdomen.” The parents said no and the child is now 16 months of age and “a laughing toddler with just a scar to show for his earlier defect.” But in a hospital memo obtained by the Alberta Report, nurses were advised earlier this year that “genetic terminations” would be done and that nurses would be responsible for every aspect of the mother’s care including the “delivery” and paperwork. The memo in question is available from “>ALL upon request.

(Reading: “Heat on Hospital, Activists Condemn Late-Term Abortions,” Calgary Sun, 5/8/99; Genetic Terminations memorandum, 2/26/99)

cloning

BIO-TECH’S DEADLY ACQUISITIONS: California-based Geron Corporation has acquired Roslin Bio-Med, the firm formed by Scotland’s Roslin Institute, home of the “Dolly clone.” Geron plans to focus on human tissue cloning and stem-cell research. The Center for Bioethics and Human Dignity (CBHD) warns, “If Geron is successful and follows through with its plan, the company will attempt to master technology that would seek to treat a patient’s disease from the cells of the patient’s embryonic genetic twin-a twin that would be killed for the cells they possess.”

BIO-TECH’S DEADLY ACQUISITIONS: California-based Geron Corporation has acquired Roslin Bio-Med, the firm formed by Scotland’s Roslin Institute, home of the “Dolly clone.” Geron plans to focus on human tissue cloning and stem-cell research. The Center for Bioethics and Human Dignity (CBHD) warns, “If Geron is successful and follows through with its plan, the company will attempt to master technology that would seek to treat a patient’s disease from the cells of the patient’s embryonic genetic twin-a twin that would be killed for the cells they possess.”

BIO-TECH’S DEADLY ACQUISITIONS: California-based Geron Corporation has acquired Roslin Bio-Med, the firm formed by Scotland’s Roslin Institute, home of the “Dolly clone.” Geron plans to focus on human tissue cloning and stem-cell research. The Center for Bioethics and Human Dignity (CBHD) warns, “If Geron is successful and follows through with its plan, the company will attempt to master technology that would seek to treat a patient’s disease from the cells of the patient’s embryonic genetic twin-a twin that would be killed for the cells they possess.”

(Reading: “Geron Aims to Clone Human Tissue for Transplants,” Fox News Online, 5/5/99; CBHD Forum “In the News: Cloning and Stem Cell Research,” 5/6/99)

(ACTION: The U.S. government is poised to fund human embryonic stem cell research and each member of Congress must be advised that such research will result in the deaths of tiny human beings who will be violated by such destructive research. Get complete background on this research, plus immediate access to members of Congress, from American Life League.)

DANGERS: Oregon researchers experimenting with the cloning of monkeys have determined that serious health risks do occur. Lab scientist Gerald Schatten said, “There are a hell of a lot of fetal and neonatal deaths along the way,” which prompted warnings that such research is “far too dangerous to consider cloning people. . . . You don’t have to know why cloned animals so often die of bizarre abnormalities to know that the same thing would happen to people. Whatever is happening to these animals is relevant to humans.” French researchers have raised similar concerns.

(Reading: “Clone Defects Point to Need for 2 Genetic Parents,” Washington Post, 5/10/99, page A1; “Cloning May Cause Long-Term Health Problems,” Reuters, 4/30/99)

imposed death

HEMLOCK SOCIETY: The recent Hemlock newsletter, Timelines, says of Jack Kevorkian, “No compassionate doctor who helps to end suffering should be subject to prosecution in a civilized country. We must back Dr. Kevorkian’s efforts with legal change and support for Hemlock’s activities. He courageously broke the law. The law is wrong. This is the time to change it if we all work together.”

HEMLOCK SOCIETY: The recent Hemlock newsletter, Timelines, says of Jack Kevorkian, “No compassionate doctor who helps to end suffering should be subject to prosecution in a civilized country. We must back Dr. Kevorkian’s efforts with legal change and support for Hemlock’s activities. He courageously broke the law. The law is wrong. This is the time to change it if we all work together.”

HEMLOCK SOCIETY: The recent Hemlock newsletter, Timelines, says of Jack Kevorkian, “No compassionate doctor who helps to end suffering should be subject to prosecution in a civilized country. We must back Dr. Kevorkian’s efforts with legal change and support for Hemlock’s activities. He courageously broke the law. The law is wrong. This is the time to change it if we all work together.”

(Reading: “Dr. Kevorkian Convicted,” Timelines, Spring, 1999, page 1)

human experimentation

OHIO: Due to growing controversy over experiments involving psychiatric patients and their treatment, the University of Cincinnati has dropped the controversial research studies. The studies involved “giving people chemicals that may induce psychosis to study its biology or to test a treatment.”

OHIO: Due to growing controversy over experiments involving psychiatric patients and their treatment, the University of Cincinnati has dropped the controversial research studies. The studies involved “giving people chemicals that may induce psychosis to study its biology or to test a treatment.”

OHIO: Due to growing controversy over experiments involving psychiatric patients and their treatment, the University of Cincinnati has dropped the controversial research studies. The studies involved “giving people chemicals that may induce psychosis to study its biology or to test a treatment.”

COMMENT: Citizens for Responsible Care and Research in New York played a major role in this current victory for the mentally disabled.

(Reading: “UC Drops Controversial Psychoses Tests, Critics Contend Studies Unethical,” Cincinnati Enquirer, 5/6/99)

(Contact: “>Citizens for Responsible Care and Research, 142 W. End Ave., Suite 28P, New York, NY 10023; Phone: 212-595-8974; Fax 212-595-9086)

organ donation

PENNSYLVANIA SALE! A new law will allow state health officials to offer a stipend of approximately $300 to families of organ donors to assist in the payment of funeral expenses. New York Times op-ed writer Jerome Groopman opines, “Would a family, overtly or subconsciously, decide to withdraw life support prematurely so as to have usable organs for donation? Might a doctor be asked by a family not to administer a treatment that had a small but finite chance of saving a life because it had a very significant chance of damaging the kidneys or lungs or heart, thereby making the patient ineligible as a donor? An open market will be created by the plan, a market for death.”

PENNSYLVANIA SALE! A new law will allow state health officials to offer a stipend of approximately $300 to families of organ donors to assist in the payment of funeral expenses. New York Times op-ed writer Jerome Groopman opines, “Would a family, overtly or subconsciously, decide to withdraw life support prematurely so as to have usable organs for donation? Might a doctor be asked by a family not to administer a treatment that had a small but finite chance of saving a life because it had a very significant chance of damaging the kidneys or lungs or heart, thereby making the patient ineligible as a donor? An open market will be created by the plan, a market for death.”

PENNSYLVANIA SALE! A new law will allow state health officials to offer a stipend of approximately $300 to families of organ donors to assist in the payment of funeral expenses. New York Times op-ed writer Jerome Groopman opines, “Would a family, overtly or subconsciously, decide to withdraw life support prematurely so as to have usable organs for donation? Might a doctor be asked by a family not to administer a treatment that had a small but finite chance of saving a life because it had a very significant chance of damaging the kidneys or lungs or heart, thereby making the patient ineligible as a donor? An open market will be created by the plan, a market for death.”

(Reading: “Pennsylvania Set to Break Taboo on Money for Organs,” New York Times, 5/6/99; “The Moral Way to Pay for Donor Organs,” New York Times, 5/7/99)

pharmacists

NEWEST OFFICER: Pharmacists for Life International announces the appointment of Karen Brauer, MS, RPh, as vice president.

NEWEST OFFICER: Pharmacists for Life International announces the appointment of Karen Brauer, MS, RPh, as vice president.

NEWEST OFFICER: Pharmacists for Life International announces the appointment of Karen Brauer, MS, RPh, as vice president.

stem cell research

BONE MARROW STEM CELLS: The Economist reports that “the results of five clinical trials, conducted in America, Canada, France, South Africa and Sweden, have just been announced by the American Society of Clinical Oncology. In only one of the trials did the use of stem-cell support and high-dose chemotherapy appear to prolong life more effectively than conventional low-dose treatments . . . the successful trial might have been a statistical fluke-meaning that the treatment is of no additional value at all.”

BONE MARROW STEM CELLS: The Economist reports that “the results of five clinical trials, conducted in America, Canada, France, South Africa and Sweden, have just been announced by the American Society of Clinical Oncology. In only one of the trials did the use of stem-cell support and high-dose chemotherapy appear to prolong life more effectively than conventional low-dose treatments . . . the successful trial might have been a statistical fluke-meaning that the treatment is of no additional value at all.”

BONE MARROW STEM CELLS: The Economist reports that “the results of five clinical trials, conducted in America, Canada, France, South Africa and Sweden, have just been announced by the American Society of Clinical Oncology. In only one of the trials did the use of stem-cell support and high-dose chemotherapy appear to prolong life more effectively than conventional low-dose treatments . . . the successful trial might have been a statistical fluke-meaning that the treatment is of no additional value at all.”

(Reading: “Breast Cancer: Try Again,” The Economist, 4/24/99, p. 79)

you

IAETF UPDATE: The January-March 1999 issue of IAETF Update provides insights on Kevorkian by Herbert Hendin, M.D., the cost-cutting side of ending lives by Wesley J. Smith, and more. To subscribe or for detailed information contact International Anti-Euthanasia Task Force.

IAETF UPDATE: The January-March 1999 issue of IAETF Update provides insights on Kevorkian by Herbert Hendin, M.D., the cost-cutting side of ending lives by Wesley J. Smith, and more. To subscribe or for detailed information contact International Anti-Euthanasia Task Force.

IAETF UPDATE: The January-March 1999 issue of IAETF Update provides insights on Kevorkian by Herbert Hendin, M.D., the cost-cutting side of ending lives by Wesley J. Smith, and more. To subscribe or for detailed information contact International Anti-Euthanasia Task Force.

PRO-LIFE PHARMACY: A full line of quality vitamins, minerals, nutritionals, homeopathic remedies and herbal products formulated for families can be obtained from American Pro-Life Enterprise.

reflect

Test me, O God, and know my thoughts; see whether I step in the wrong path, and guide me along the everlasting way.

-Psalm 138:23-24

pray

Thank you, Lord, for your patient love as I struggle to be your good servant. Amen.

FLORIDA: James Scott Pendegraft IV, MD, sent a letter announcing the opening of his newest abortion mill, Ft. Lauderdale Women’s Center, (FLWC). He wrote “To obtain a pregnancy termination beyond 24 weeks gestation, Florida state law requires that a patient receive a written statement from her personal physician indicating it would be a threat to her health to continue the pregnancy. Additionally, FLWC will offer chemically induced terminations using the combination of Methotrexate and Misoprostol between 3 to 9 weeks gestation for those patients who prefer to not undergo a procedure which involves the use of surgical instruments. Manual Vacuum Aspiration (MVA) can also be performed on patients between three to nine weeks gestation if the patient chooses.” Pendegraft describes himself as a perinatologist and board-certified Ob/Gyn.

James Scott Pendegraft IV, MD, sent a letter announcing the opening of his newest abortion mill, Ft. Lauderdale Women’s Center, (FLWC). He wrote “To obtain a pregnancy termination beyond 24 weeks gestation, Florida state law requires that a patient receive a written statement from her personal physician indicating it would be a threat to her health to continue the pregnancy. Additionally, FLWC will offer chemically induced terminations using the combination of Methotrexate and Misoprostol between 3 to 9 weeks gestation for those patients who prefer to not undergo a procedure which involves the use of surgical instruments. Manual Vacuum Aspiration (MVA) can also be performed on patients between three to nine weeks gestation if the patient chooses.” Pendegraft describes himself as a perinatologist and board-certified Ob/Gyn.

(Reading: 4/14/99 letter to Kathi A. Aultman, MD from James Scott Pendegraft IV, M.D.)

GENETIC TERMINATION: The Calgary Sun reports on one child whose parents were told to abort him at 24 weeks because “his small bowel was forming outside his abdomen.” The parents said no and the child is now 16 months of age and “a laughing toddler with just a scar to show for his earlier defect.” But in a hospital memo obtained by the Alberta Report, nurses were advised earlier this year that “genetic terminations” would be done and that nurses would be responsible for every aspect of the mother’s care including the “delivery” and paperwork. The memo in question is available from “>ALL upon request.

(Reading: “Heat on Hospital, Activists Condemn Late-Term Abortions,” Calgary Sun, 5/8/99; Genetic Terminations memorandum, 2/26/99)

cloning

BIO-TECH’S DEADLY ACQUISITIONS: California-based Geron Corporation has acquired Roslin Bio-Med, the firm formed by Scotland’s Roslin Institute, home of the “Dolly clone.” Geron plans to focus on human tissue cloning and stem-cell research. The Center for Bioethics and Human Dignity (CBHD) warns, “If Geron is successful and follows through with its plan, the company will attempt to master technology that would seek to treat a patient’s disease from the cells of the patient’s embryonic genetic twin-a twin that would be killed for the cells they possess.”

BIO-TECH’S DEADLY ACQUISITIONS: California-based Geron Corporation has acquired Roslin Bio-Med, the firm formed by Scotland’s Roslin Institute, home of the “Dolly clone.” Geron plans to focus on human tissue cloning and stem-cell research. The Center for Bioethics and Human Dignity (CBHD) warns, “If Geron is successful and follows through with its plan, the company will attempt to master technology that would seek to treat a patient’s disease from the cells of the patient’s embryonic genetic twin-a twin that would be killed for the cells they possess.”

BIO-TECH’S DEADLY ACQUISITIONS: California-based Geron Corporation has acquired Roslin Bio-Med, the firm formed by Scotland’s Roslin Institute, home of the “Dolly clone.” Geron plans to focus on human tissue cloning and stem-cell research. The Center for Bioethics and Human Dignity (CBHD) warns, “If Geron is successful and follows through with its plan, the company will attempt to master technology that would seek to treat a patient’s disease from the cells of the patient’s embryonic genetic twin-a twin that would be killed for the cells they possess.”

(Reading: “Geron Aims to Clone Human Tissue for Transplants,” Fox News Online, 5/5/99; CBHD Forum “In the News: Cloning and Stem Cell Research,” 5/6/99)

(ACTION: The U.S. government is poised to fund human embryonic stem cell research and each member of Congress must be advised that such research will result in the deaths of tiny human beings who will be violated by such destructive research. Get complete background on this research, plus immediate access to members of Congress, from American Life League.)

DANGERS: Oregon researchers experimenting with the cloning of monkeys have determined that serious health risks do occur. Lab scientist Gerald Schatten said, “There are a hell of a lot of fetal and neonatal deaths along the way,” which prompted warnings that such research is “far too dangerous to consider cloning people. . . . You don’t have to know why cloned animals so often die of bizarre abnormalities to know that the same thing would happen to people. Whatever is happening to these animals is relevant to humans.” French researchers have raised similar concerns.

(Reading: “Clone Defects Point to Need for 2 Genetic Parents,” Washington Post, 5/10/99, page A1; “Cloning May Cause Long-Term Health Problems,” Reuters, 4/30/99)

imposed death

HEMLOCK SOCIETY: The recent Hemlock newsletter, Timelines, says of Jack Kevorkian, “No compassionate doctor who helps to end suffering should be subject to prosecution in a civilized country. We must back Dr. Kevorkian’s efforts with legal change and support for Hemlock’s activities. He courageously broke the law. The law is wrong. This is the time to change it if we all work together.”

HEMLOCK SOCIETY: The recent Hemlock newsletter, Timelines, says of Jack Kevorkian, “No compassionate doctor who helps to end suffering should be subject to prosecution in a civilized country. We must back Dr. Kevorkian’s efforts with legal change and support for Hemlock’s activities. He courageously broke the law. The law is wrong. This is the time to change it if we all work together.”

HEMLOCK SOCIETY: The recent Hemlock newsletter, Timelines, says of Jack Kevorkian, “No compassionate doctor who helps to end suffering should be subject to prosecution in a civilized country. We must back Dr. Kevorkian’s efforts with legal change and support for Hemlock’s activities. He courageously broke the law. The law is wrong. This is the time to change it if we all work together.”

(Reading: “Dr. Kevorkian Convicted,” Timelines, Spring, 1999, page 1)

human experimentation

OHIO: Due to growing controversy over experiments involving psychiatric patients and their treatment, the University of Cincinnati has dropped the controversial research studies. The studies involved “giving people chemicals that may induce psychosis to study its biology or to test a treatment.”

OHIO: Due to growing controversy over experiments involving psychiatric patients and their treatment, the University of Cincinnati has dropped the controversial research studies. The studies involved “giving people chemicals that may induce psychosis to study its biology or to test a treatment.”

OHIO: Due to growing controversy over experiments involving psychiatric patients and their treatment, the University of Cincinnati has dropped the controversial research studies. The studies involved “giving people chemicals that may induce psychosis to study its biology or to test a treatment.”

COMMENT: Citizens for Responsible Care and Research in New York played a major role in this current victory for the mentally disabled.

(Reading: “UC Drops Controversial Psychoses Tests, Critics Contend Studies Unethical,” Cincinnati Enquirer, 5/6/99)

(Contact: “>Citizens for Responsible Care and Research, 142 W. End Ave., Suite 28P, New York, NY 10023; Phone: 212-595-8974; Fax 212-595-9086)

organ donation

PENNSYLVANIA SALE! A new law will allow state health officials to offer a stipend of approximately $300 to families of organ donors to assist in the payment of funeral expenses. New York Times op-ed writer Jerome Groopman opines, “Would a family, overtly or subconsciously, decide to withdraw life support prematurely so as to have usable organs for donation? Might a doctor be asked by a family not to administer a treatment that had a small but finite chance of saving a life because it had a very significant chance of damaging the kidneys or lungs or heart, thereby making the patient ineligible as a donor? An open market will be created by the plan, a market for death.”

PENNSYLVANIA SALE! A new law will allow state health officials to offer a stipend of approximately $300 to families of organ donors to assist in the payment of funeral expenses. New York Times op-ed writer Jerome Groopman opines, “Would a family, overtly or subconsciously, decide to withdraw life support prematurely so as to have usable organs for donation? Might a doctor be asked by a family not to administer a treatment that had a small but finite chance of saving a life because it had a very significant chance of damaging the kidneys or lungs or heart, thereby making the patient ineligible as a donor? An open market will be created by the plan, a market for death.”

PENNSYLVANIA SALE! A new law will allow state health officials to offer a stipend of approximately $300 to families of organ donors to assist in the payment of funeral expenses. New York Times op-ed writer Jerome Groopman opines, “Would a family, overtly or subconsciously, decide to withdraw life support prematurely so as to have usable organs for donation? Might a doctor be asked by a family not to administer a treatment that had a small but finite chance of saving a life because it had a very significant chance of damaging the kidneys or lungs or heart, thereby making the patient ineligible as a donor? An open market will be created by the plan, a market for death.”

(Reading: “Pennsylvania Set to Break Taboo on Money for Organs,” New York Times, 5/6/99; “The Moral Way to Pay for Donor Organs,” New York Times, 5/7/99)

pharmacists

NEWEST OFFICER: Pharmacists for Life International announces the appointment of Karen Brauer, MS, RPh, as vice president.

NEWEST OFFICER: Pharmacists for Life International announces the appointment of Karen Brauer, MS, RPh, as vice president.

NEWEST OFFICER: Pharmacists for Life International announces the appointment of Karen Brauer, MS, RPh, as vice president.

stem cell research

BONE MARROW STEM CELLS: The Economist reports that “the results of five clinical trials, conducted in America, Canada, France, South Africa and Sweden, have just been announced by the American Society of Clinical Oncology. In only one of the trials did the use of stem-cell support and high-dose chemotherapy appear to prolong life more effectively than conventional low-dose treatments . . . the successful trial might have been a statistical fluke-meaning that the treatment is of no additional value at all.”

BONE MARROW STEM CELLS: The Economist reports that “the results of five clinical trials, conducted in America, Canada, France, South Africa and Sweden, have just been announced by the American Society of Clinical Oncology. In only one of the trials did the use of stem-cell support and high-dose chemotherapy appear to prolong life more effectively than conventional low-dose treatments . . . the successful trial might have been a statistical fluke-meaning that the treatment is of no additional value at all.”

BONE MARROW STEM CELLS: The Economist reports that “the results of five clinical trials, conducted in America, Canada, France, South Africa and Sweden, have just been announced by the American Society of Clinical Oncology. In only one of the trials did the use of stem-cell support and high-dose chemotherapy appear to prolong life more effectively than conventional low-dose treatments . . . the successful trial might have been a statistical fluke-meaning that the treatment is of no additional value at all.”

(Reading: “Breast Cancer: Try Again,” The Economist, 4/24/99, p. 79)

you

IAETF UPDATE: The January-March 1999 issue of IAETF Update provides insights on Kevorkian by Herbert Hendin, M.D., the cost-cutting side of ending lives by Wesley J. Smith, and more. To subscribe or for detailed information contact International Anti-Euthanasia Task Force.

IAETF UPDATE: The January-March 1999 issue of IAETF Update provides insights on Kevorkian by Herbert Hendin, M.D., the cost-cutting side of ending lives by Wesley J. Smith, and more. To subscribe or for detailed information contact International Anti-Euthanasia Task Force.

IAETF UPDATE: The January-March 1999 issue of IAETF Update provides insights on Kevorkian by Herbert Hendin, M.D., the cost-cutting side of ending lives by Wesley J. Smith, and more. To subscribe or for detailed information contact International Anti-Euthanasia Task Force.

PRO-LIFE PHARMACY: A full line of quality vitamins, minerals, nutritionals, homeopathic remedies and herbal products formulated for families can be obtained from American Pro-Life Enterprise.

reflect

Test me, O God, and know my thoughts; see whether I step in the wrong path, and guide me along the everlasting way.

-Psalm 138:23-24

pray

Thank you, Lord, for your patient love as I struggle to be your good servant. Amen.

FLORIDA: James Scott Pendegraft IV, MD, sent a letter announcing the opening of his newest abortion mill, Ft. Lauderdale Women’s Center, (FLWC). He wrote “To obtain a pregnancy termination beyond 24 weeks gestation, Florida state law requires that a patient receive a written statement from her personal physician indicating it would be a threat to her health to continue the pregnancy. Additionally, FLWC will offer chemically induced terminations using the combination of Methotrexate and Misoprostol between 3 to 9 weeks gestation for those patients who prefer to not undergo a procedure which involves the use of surgical instruments. Manual Vacuum Aspiration (MVA) can also be performed on patients between three to nine weeks gestation if the patient chooses.” Pendegraft describes himself as a perinatologist and board-certified Ob/Gyn.

(Reading: 4/14/99 letter to Kathi A. Aultman, MD from James Scott Pendegraft IV, M.D.)

GENETIC TERMINATION: The Calgary Sun reports on one child whose parents were told to abort him at 24 weeks because “his small bowel was forming outside his abdomen.” The parents said no and the child is now 16 months of age and “a laughing toddler with just a scar to show for his earlier defect.” But in a hospital memo obtained by the Alberta Report, nurses were advised earlier this year that “genetic terminations” would be done and that nurses would be responsible for every aspect of the mother’s care including the “delivery” and paperwork. The memo in question is available from “>ALL upon request.

(Reading: “Heat on Hospital, Activists Condemn Late-Term Abortions,” Calgary Sun, 5/8/99; Genetic Terminations memorandum, 2/26/99)

cloning

BIO-TECH’S DEADLY ACQUISITIONS: California-based Geron Corporation has acquired Roslin Bio-Med, the firm formed by Scotland’s Roslin Institute, home of the “Dolly clone.” Geron plans to focus on human tissue cloning and stem-cell research. The Center for Bioethics and Human Dignity (CBHD) warns, “If Geron is successful and follows through with its plan, the company will attempt to master technology that would seek to treat a patient’s disease from the cells of the patient’s embryonic genetic twin-a twin that would be killed for the cells they possess.”

BIO-TECH’S DEADLY ACQUISITIONS: California-based Geron Corporation has acquired Roslin Bio-Med, the firm formed by Scotland’s Roslin Institute, home of the “Dolly clone.” Geron plans to focus on human tissue cloning and stem-cell research. The Center for Bioethics and Human Dignity (CBHD) warns, “If Geron is successful and follows through with its plan, the company will attempt to master technology that would seek to treat a patient’s disease from the cells of the patient’s embryonic genetic twin-a twin that would be killed for the cells they possess.”

BIO-TECH’S DEADLY ACQUISITIONS: California-based Geron Corporation has acquired Roslin Bio-Med, the firm formed by Scotland’s Roslin Institute, home of the “Dolly clone.” Geron plans to focus on human tissue cloning and stem-cell research. The Center for Bioethics and Human Dignity (CBHD) warns, “If Geron is successful and follows through with its plan, the company will attempt to master technology that would seek to treat a patient’s disease from the cells of the patient’s embryonic genetic twin-a twin that would be killed for the cells they possess.”

(Reading: “Geron Aims to Clone Human Tissue for Transplants,” Fox News Online, 5/5/99; CBHD Forum “In the News: Cloning and Stem Cell Research,” 5/6/99)

(ACTION: The U.S. government is poised to fund human embryonic stem cell research and each member of Congress must be advised that such research will result in the deaths of tiny human beings who will be violated by such destructive research. Get complete background on this research, plus immediate access to members of Congress, from American Life League.)

DANGERS: Oregon researchers experimenting with the cloning of monkeys have determined that serious health risks do occur. Lab scientist Gerald Schatten said, “There are a hell of a lot of fetal and neonatal deaths along the way,” which prompted warnings that such research is “far too dangerous to consider cloning people. . . . You don’t have to know why cloned animals so often die of bizarre abnormalities to know that the same thing would happen to people. Whatever is happening to these animals is relevant to humans.” French researchers have raised similar concerns.

(Reading: “Clone Defects Point to Need for 2 Genetic Parents,” Washington Post, 5/10/99, page A1; “Cloning May Cause Long-Term Health Problems,” Reuters, 4/30/99)

imposed death

HEMLOCK SOCIETY: The recent Hemlock newsletter, Timelines, says of Jack Kevorkian, “No compassionate doctor who helps to end suffering should be subject to prosecution in a civilized country. We must back Dr. Kevorkian’s efforts with legal change and support for Hemlock’s activities. He courageously broke the law. The law is wrong. This is the time to change it if we all work together.”

HEMLOCK SOCIETY: The recent Hemlock newsletter, Timelines, says of Jack Kevorkian, “No compassionate doctor who helps to end suffering should be subject to prosecution in a civilized country. We must back Dr. Kevorkian’s efforts with legal change and support for Hemlock’s activities. He courageously broke the law. The law is wrong. This is the time to change it if we all work together.”

HEMLOCK SOCIETY: The recent Hemlock newsletter, Timelines, says of Jack Kevorkian, “No compassionate doctor who helps to end suffering should be subject to prosecution in a civilized country. We must back Dr. Kevorkian’s efforts with legal change and support for Hemlock’s activities. He courageously broke the law. The law is wrong. This is the time to change it if we all work together.”

(Reading: “Dr. Kevorkian Convicted,” Timelines, Spring, 1999, page 1)

human experimentation

OHIO: Due to growing controversy over experiments involving psychiatric patients and their treatment, the University of Cincinnati has dropped the controversial research studies. The studies involved “giving people chemicals that may induce psychosis to study its biology or to test a treatment.”

OHIO: Due to growing controversy over experiments involving psychiatric patients and their treatment, the University of Cincinnati has dropped the controversial research studies. The studies involved “giving people chemicals that may induce psychosis to study its biology or to test a treatment.”

OHIO: Due to growing controversy over experiments involving psychiatric patients and their treatment, the University of Cincinnati has dropped the controversial research studies. The studies involved “giving people chemicals that may induce psychosis to study its biology or to test a treatment.”

COMMENT: Citizens for Responsible Care and Research in New York played a major role in this current victory for the mentally disabled.

(Reading: “UC Drops Controversial Psychoses Tests, Critics Contend Studies Unethical,” Cincinnati Enquirer, 5/6/99)

(Contact: “>Citizens for Responsible Care and Research, 142 W. End Ave., Suite 28P, New York, NY 10023; Phone: 212-595-8974; Fax 212-595-9086)

organ donation

PENNSYLVANIA SALE! A new law will allow state health officials to offer a stipend of approximately $300 to families of organ donors to assist in the payment of funeral expenses. New York Times op-ed writer Jerome Groopman opines, “Would a family, overtly or subconsciously, decide to withdraw life support prematurely so as to have usable organs for donation? Might a doctor be asked by a family not to administer a treatment that had a small but finite chance of saving a life because it had a very significant chance of damaging the kidneys or lungs or heart, thereby making the patient ineligible as a donor? An open market will be created by the plan, a market for death.”

PENNSYLVANIA SALE! A new law will allow state health officials to offer a stipend of approximately $300 to families of organ donors to assist in the payment of funeral expenses. New York Times op-ed writer Jerome Groopman opines, “Would a family, overtly or subconsciously, decide to withdraw life support prematurely so as to have usable organs for donation? Might a doctor be asked by a family not to administer a treatment that had a small but finite chance of saving a life because it had a very significant chance of damaging the kidneys or lungs or heart, thereby making the patient ineligible as a donor? An open market will be created by the plan, a market for death.”

PENNSYLVANIA SALE! A new law will allow state health officials to offer a stipend of approximately $300 to families of organ donors to assist in the payment of funeral expenses. New York Times op-ed writer Jerome Groopman opines, “Would a family, overtly or subconsciously, decide to withdraw life support prematurely so as to have usable organs for donation? Might a doctor be asked by a family not to administer a treatment that had a small but finite chance of saving a life because it had a very significant chance of damaging the kidneys or lungs or heart, thereby making the patient ineligible as a donor? An open market will be created by the plan, a market for death.”

(Reading: “Pennsylvania Set to Break Taboo on Money for Organs,” New York Times, 5/6/99; “The Moral Way to Pay for Donor Organs,” New York Times, 5/7/99)

pharmacists

NEWEST OFFICER: Pharmacists for Life International announces the appointment of Karen Brauer, MS, RPh, as vice president.

NEWEST OFFICER: Pharmacists for Life International announces the appointment of Karen Brauer, MS, RPh, as vice president.

NEWEST OFFICER: Pharmacists for Life International announces the appointment of Karen Brauer, MS, RPh, as vice president.

stem cell research

BONE MARROW STEM CELLS: The Economist reports that “the results of five clinical trials, conducted in America, Canada, France, South Africa and Sweden, have just been announced by the American Society of Clinical Oncology. In only one of the trials did the use of stem-cell support and high-dose chemotherapy appear to prolong life more effectively than conventional low-dose treatments . . . the successful trial might have been a statistical fluke-meaning that the treatment is of no additional value at all.”

BONE MARROW STEM CELLS: The Economist reports that “the results of five clinical trials, conducted in America, Canada, France, South Africa and Sweden, have just been announced by the American Society of Clinical Oncology. In only one of the trials did the use of stem-cell support and high-dose chemotherapy appear to prolong life more effectively than conventional low-dose treatments . . . the successful trial might have been a statistical fluke-meaning that the treatment is of no additional value at all.”

BONE MARROW STEM CELLS: The Economist reports that “the results of five clinical trials, conducted in America, Canada, France, South Africa and Sweden, have just been announced by the American Society of Clinical Oncology. In only one of the trials did the use of stem-cell support and high-dose chemotherapy appear to prolong life more effectively than conventional low-dose treatments . . . the successful trial might have been a statistical fluke-meaning that the treatment is of no additional value at all.”

(Reading: “Breast Cancer: Try Again,” The Economist, 4/24/99, p. 79)

you

IAETF UPDATE: The January-March 1999 issue of IAETF Update provides insights on Kevorkian by Herbert Hendin, M.D., the cost-cutting side of ending lives by Wesley J. Smith, and more. To subscribe or for detailed information contact International Anti-Euthanasia Task Force.

IAETF UPDATE: The January-March 1999 issue of IAETF Update provides insights on Kevorkian by Herbert Hendin, M.D., the cost-cutting side of ending lives by Wesley J. Smith, and more. To subscribe or for detailed information contact International Anti-Euthanasia Task Force.

IAETF UPDATE: The January-March 1999 issue of IAETF Update provides insights on Kevorkian by Herbert Hendin, M.D., the cost-cutting side of ending lives by Wesley J. Smith, and more. To subscribe or for detailed information contact International Anti-Euthanasia Task Force.

PRO-LIFE PHARMACY: A full line of quality vitamins, minerals, nutritionals, homeopathic remedies and herbal products formulated for families can be obtained from American Pro-Life Enterprise.

reflect

Test me, O God, and know my thoughts; see whether I step in the wrong path, and guide me along the everlasting way.

-Psalm 138:23-24

pray

Thank you, Lord, for your patient love as I struggle to be your good servant. Amen.